Plain-English translation of NCT07239323 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called in vivo CAR-T cell therapy for people with blood cancers that have come back or stopped responding to standard treatments. CAR-T therapy works by taking your own immune cells and preparing them to recognize and attack cancer cells. The study will track how well this treatment works and monitor you for side effects over two years.
Many people with blood cancers like leukemia, lymphoma, and multiple myeloma find that standard treatments stop working over time. This trial exists to see if this new approach using your own immune system can help patients whose cancers have become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive one intravenous infusion of the new immune cell therapy. You will then be hospitalized for observation to monitor your safety and how you respond. After that, you'll have follow-up visits and evaluations over the course of two years to see how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China